Dr. Kipps’ Notes
At the recent American Society of Clinical Oncology meeting, Dr. Kipps helped lead a discussion on the ‘Expanded Understanding of CLL Biology’. Educational sessions help to disseminate current research to other oncologists. Dr. Kipps also
wrote an educational manuscript, “Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy.” Our goal is to make discoveries and to help others understand the significance of discoveries. |
Related Links
|
Understanding the Biology of Cancer
The Blood Cancer Research Fund is involved in discovering the
underlying biology of blood cancers. Genetic markers are
becoming increasingly important in determining disease
aggressiveness and potentially effective therapeutic strategies.
With the volume of research being produced each year, we are
getting increasingly close to solving the cancer puzzle! 
The Blood Cancer Research Fund, under the leadership of Dr.
Thomas J. Kipps, is immersed in discovering the biology of
cancer. By understanding the subtle changes in genetics,
signaling pathways, and other areas we can identify ways to
stop cancer. Emerging technologies such as cytogenetics are
becoming increasing important in making effective clinical
decisions. For instance, we helped to show that patients with
leukemic cells that have a deletions at chromosome 11q or
17p or have an additional chromosome 12, do better with
different treatment strategies than patients lacking those
chromosomal changes. Identifying biologic and genetic changes
that occur in patients is important for more than prognostic significance, but
also for uncovering the mechanisms that enable cancer to survive and
function.
BCRF Awards and Recognition
The American Society of Clinical Oncology, ASCO, recently honored
the work of one of the Blood Cancer Research Fund talented Clinician
Researchers. Danelle James, MD, received the ‘Young Investigator Award’,
for her work on, "The Impact of Revlimid on CLL Microenvironment". This ties
in directly with an active clinical trial testing the efficacy of Revelimid +
Rituximab in patients with CLL.
The University of California, San Diego was awarded the American
Society of Hematology (ASH) 2009, Trainee Research Award, recognizing Dr.
Kipps work with a BCRF research fellow, Han-Yu Chuang, PhD. The goal
of this award is to expose trainees to hematology research early in their
career and hopefully encourage them continue research as part of their future
training. Working in the Blood Cancer Research Fund the Kipps’ Lab provides
exposure to a wide array of hematologic research.
The Future of Personalized Cancer Treatment: An Entirely New Direction for RNAi Delivery
In technology that promises to one day allow drug delivery to be tailored to an individual patient and a particular cancer tumor, researchers at the University of California, San Diego School of Medicine, have developed an efficient system for delivering siRNA, which interferes with gene expression, into primary cells. The work will be published in the May 17 in the advance on-line edition of Nature Biotechnology.
“RNAi has an unbelievable potential to manage cancer and treat it,” said Steven Dowdy, PhD, Howard Hughes Medical Institute Investigator and professor of cellular and molecular medicine at UC San Diego School of Medicine. “While there's still a long way to go, we have successfully developed a technology that allows for siRNA drug delivery into the entire population of cells, both primary and tumor-causing, without being toxic to the cells.”
Article is coninued CLICK HERE
|
Journal Blood: Current Issue
|
